Clinical and laboratory-based risk factors for the development of post-thrombotic syndrome (PTS) in children with provoked deep venous thrombosis (DVT): findings from the Kids-DOTT trial and biobank Clinical and laboratory-based risk factors for the development of post-thrombotic syndrome (PTS) in children with provoked deep venous thrombosis (DVT): findings from the Kids-DOTT trial and biobank

Clinical and laboratory-based risk factors for the development of post-thrombotic syndrome (PTS) in children with provoked deep venous thrombosis (DVT): findings from the Kids-DOTT trial and biobank

June 25, 2024 | Marisol Betensky, M.D., M.P.H.; Johns Hopkins All Children’s Hospital; St. Petersburg, FL, U.S.

Read more
Targeting autoreactive B cells using ADAMTS13-based chimeric auto-antigen receptors (CAARs) T cells for the treatment of immune thrombotic thrombocytopenic purpura (iTTP) Targeting autoreactive B cells using ADAMTS13-based chimeric auto-antigen receptors (CAARs) T cells for the treatment of immune thrombotic thrombocytopenic purpura (iTTP)

Targeting autoreactive B cells using ADAMTS13-based chimeric auto-antigen receptors (CAARs) T cells for the treatment of immune thrombotic thrombocytopenic purpura (iTTP)

June 25, 2024 | Vijay Bhoj, M.D., Ph.D.; University of Pennsylvania; Philadelphia, PA, U.S.

Read more
RSS
1234